Heranba Industries has officially published its unaudited financial results for the quarter ended June 30, 2026, in multiple newspapers across India. The publication serves as the formal regulatory disclosure following the Board of Directors' approval of the results on August 22, 2026.

The company notified stock exchanges that the results were printed in both English and regional language editions to ensure broad dissemination among stakeholders.

Publication Details

The financial results were published in the following newspapers:

• Financial Express – English (Ahmedabad), dated August 24, 2026
• Financial Express – Gujarati (Ahmedabad), dated August 24, 2026
• Financial Express – English (Mumbai), dated August 23, 2026
• Mumbai Lakshadweep – Marathi (Mumbai), dated August 23, 2026

Abdul Latif, Company Secretary and Compliance Officer, signed the communication confirming the publications.

Financial Performance

Consolidated revenue from operations stood at ₹383.20 crore in Q1FY27, up from ₹452.43 crore in Q1FY26 but significantly higher than the ₹319.48 crore recorded in Q4FY26. The company returned to profitability after posting a consolidated loss of ₹58.32 crore in the previous quarter.

Standalone results showed a net profit of ₹9.46 crore for the quarter, compared to a loss of ₹12.50 crore in Q4FY26 and a profit of ₹22.02 crore in Q1FY26. Standalone revenue was ₹364.99 crore.

What the Numbers Show

A significant divergence exists between standalone and consolidated tax treatments. While standalone operations generated a pre-tax profit of ₹13.41 crore with a modest tax expense of ₹3.95 crore, the consolidated group reported a higher pre-tax profit of ₹20.10 crore but incurred a substantially larger tax expense of ₹13.07 crore. This elevated consolidated tax burden, driven largely by a deferred tax charge of ₹8.92 crore, reduced the bottom-line impact of the operational turnaround, resulting in a lower consolidated net profit relative to the standalone figure.

Corporate Developments

The Board approved an investment of up to ₹25 crore in the share capital of Mikusu India Private Limited, a wholly owned subsidiary, through a right issue. The transaction is described as being undertaken in the ordinary course of business at arm's length.

Mikusu India, incorporated on April 9, 2022, is engaged in the trading of agrochemical products. It reported a turnover of ₹182.68 crore as on March 31, 2026, up from ₹152.40 crore in FY25 and ₹92.91 crore in FY24. The investment aims to support the business operations and growth plans of the subsidiary. There will be no change in Heranba Industries’ shareholding structure, as it will continue to hold 100% of the share capital.

Additionally, Mr. Punit H. Vyas, currently serving as Quality Control - Head, has been designated as Senior Management Personnel effective August 22, 2026.

Heranba Industries has designated Punit H. Vyas as Senior Management Personnel effective August 22, 2026. The Board of Directors approved the appointment during its meeting held on Saturday, August 22, 2026.

Vyas currently serves as the Quality Control - Head of the company. The designation aligns with compliance requirements under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The move formalizes his role within the senior leadership structure.

Leadership Profile

Mr. Punit H. Vyas holds an M.Sc. in Applied Chemistry from The Maharaja Sayajirao University of Baroda. He possesses over 25 years of experience in Quality Assurance, Quality Control, Regulatory Compliance, and Laboratory Operations across pharmaceutical, specialty chemicals, and agrochemical industries.

Prior to joining Heranba Industries, Vyas held senior leadership positions at PI Industries Limited, Navin Fluorine International Limited, ZCL Chemicals Limited (Zandu Pharma), J.B. Chemicals & Pharmaceuticals Limited, Cadila Pharmaceuticals Limited, Sanofi-Aventis Pharmaceuticals Limited, and Wockhardt Pharmaceuticals Limited.

He is an FDA Approved Chemist recognized by Gujarat State Authorities. His expertise includes handling audits by USFDA, EDQM, TGA, and WHO, as well as implementing Quality Management Systems and NABL compliance.

The company stated that Vyas's extensive industry experience will contribute to strengthening quality systems and operational excellence.